31.1 C
Vientiane
Sunday, May 11, 2025
spot_img
Home Blog Page 124

CGTN: Unboxing economic policy tools: What’s behind China’s latest CPC leadership meeting?

BEIJING, April 26, 2025 /PRNewswire/ — CGTN published an article on China’s latest leadership meeting on the economic situation and work. Exploring the country’s economic policy tools, the article highlights the strong resilience and potential of the Chinese economy. It also takes a look at the meeting’s stress on enhanced efforts to accelerate the implementation of more proactive and effective macro policies, as well as boosting services consumption to strengthen the overall role of consumption in driving economic growth.

China’s economy delivered a strong start in the first quarter of the year, demonstrating steady performance and resilience.

The country’s GDP grew 5.4 percent year on year to 31.8758 trillion yuan (about $4.42 trillion) in Q1 2025, ranking among the highest of the world’s major economies and positioning the country to better weather global uncertainties.

During a meeting held by the Political Bureau of the Communist Party of China Central Committee on Friday, the Chinese leadership analyzed and studied the current economic situation and economic work.

Noting that the country has seen its economy improve this year, with public confidence continuously boosted and solid progress made in high-quality development, the meeting called for efforts to accelerate the implementation of more proactive and effective macro policies and boost service consumption to strengthen the role of consumption in driving economic growth.

More proactive, effective macro policies

Besides the GDP, China has seen other economic indicators exceeding market expectations in the first quarter. For example, fixed-asset investment went up 4.2 percent year on year, with investment in infrastructure construction rising 5.8 percent and manufacturing investment increasing 9.1 percent.

Thanks to policy support, local-level responsiveness and the rapid buildup of innovation-driven momentum, the country’s economy showcases strong resilience and potential.

China has made thorough policy preparations to address external changes, as a series of targeted macro policies have already taken effect, and more incremental policies will be introduced as needed to mitigate external shocks.

Friday’s meeting called for efforts to make full use of a more proactive fiscal policy and a moderately loose monetary policy, coordinate domestic economic work and endeavors in the international economic and trade field, unswervingly manage the country’s own affairs well, and keep employment, businesses, markets and expectations stable.

Luo Zhiheng, chief economist at Yuekai Securities, said efforts should be made to make good use of aggregate and structural policy tools, cut the reserve requirement ratios and interest rates when appropriate, and boost consumption and corporate investment demand.

A multi-pronged approach for struggling enterprises

To aid businesses facing challenges, the meeting urged a multi-pronged approach, including stronger financial support and accelerating integration between domestic and foreign trade development.

Stressing the need to ensure people’s livelihood, it said that for enterprises that suffered relatively bigger impacts from tariffs, the proportion of unemployment insurance funds returned to enterprises to keep payrolls stable will be increased.

Amid recent U.S. tariff hikes, China’s foreign trade enterprises are actively responding with innovative products, seizing orders and expanding markets.

The country has also taken swift and proactive measures to cope with tariff shocks – reaching out to broader overseas markets while bolstering domestic sales channels with upgraded products.

Bai Wenxi, vice chairman of the China Enterprise Capital Alliance, urged the use of policies such as financial support and consumption coupon subsidies to further support foreign trade enterprises and continue to increase financial subsidies for export-to-domestic enterprises.

Boosting service consumption

Friday’s meeting also highlighted the need to boost service consumption, urging a swift removal of restrictive measures in the consumption sector and proposing to introduce a re-lending facility for service consumption and elderly care.

Service consumption has gradually become a new engine of economic growth and an important area for tapping consumption potential. In the first quarter of 2025, retail sales of consumer goods, a major indicator of the country’s consumption strength, gained 4.6 percent year on year.

Supported by targeted policies to boost consumption, service-related spending also picked up pace. In the first quarter, retail sales of services grew 5 percent year on year.

In addition, a series of documents to boost service consumption are implemented intensively. For instance, Chinese authorities have unveiled a work plan to boost service consumption in 2025 and released a series of new measures aimed at expanding and upgrading consumption in the domestic services sector as part of broader efforts to stimulate domestic demand.

A report released by a think tank, the China Institute for Reform and Development, forecasts that by 2030, the per capita services consumption of China’s urban and rural residents could exceed 20,000 yuan, accounting for more than half of total consumption.

Services consumption has become a propeller of goods consumption, and a “goods-like services” trend is gaining momentum across the country, said Chi Fulin, head of the think tank.

For more information, please click:
https://news.cgtn.com/news/2025-04-25/Unboxing-China-s-economic-policy-tools-after-latest-leadership-meeting-1CRzRDF2bLi/p.html 

CCTV4: 20th China Film Huabiao Awards

BEIJING, April 26, 2025 /PRNewswire/ — The latest data from the National Film Administration have revealed that the box office revenue of the mainland Chinese film market has already passed the 25 billion yuan (US$3.4 billion) mark in 2025. This compares to 42.5 billion yuan (US$5.8 billion) for the whole of last year, and shows that Chinese cinema is continuing to dominate the global film market. In 2025, the world is celebrating 130 years of cinema and China is marking the 120th anniversary of its own film industry. On April 27th Qingdao in Shandong Province is hosting the 20th China Film Huabiao Awards ceremony. Hundreds of industry luminaries will gather for the event, the theme of which is “Building Dreams through Film, Embracing the Spirit of the Era”. Together they will honor the collaborative and pioneering spirit of China’s filmmakers and celebrate the outstanding progress made by its film sector. The gala will be broadcast live on the CCTV-6 Movie Channel and the CCTV-4 Chinese International Channel, with simultaneous online coverage on China Media Group’s multi-platform networks, the Movie Channel’s own digital ecosystem, and other online platforms.

20th China Film Huabiao Awards
20th China Film Huabiao Awards

 

The New DePin: OKZOO’s Environmental AIoT Machine Network Leads New Tech Trend

HO CHI MINH CITY, Vietnam, April 26, 2025 /PRNewswire/ — The “new DePin” (Decentralized Physical Infrastructure Network) trend is arising, as OKZOO’s AIoT devices see explosive growth and traction.

AIoT is short for AI combined with Internet of Things (AIoT), a new category that bridges physical hardware with decentralized network. OKZOO uses AIoT devices to gather environmental data such as noise pollution, air pollution, CO2 levels, and humidity.

OKZOO has already seen massive adoption with 12 million ecosystem users, primarily through its virtual AI pet apps OKZOO V1 and V2.

How AI Pets and Portal Devices Collect Environmental Data

OKZOO’s development began with an intriguing hypothesis: could engaging pet applications serve as the foundation for sophisticated real-world AIoT networks? The team systematically validated this concept through strategic platform iterations.

Their V1 release, a straightforward pet simulator, attracted 7 million users, demonstrating that emotional connections remain powerful in today’s digital landscape. Following this achievement, V2 introduced AI-powered pets capable of learning and evolution, gaining 700,000 users within its initial month.

This validated market traction led to the creation of the P-mini—a compact AIoT device that integrates digital pets with environmental monitoring technology. The P-mini o1 incorporates both sensor technology and an interactive AI companion that reacts to environmental conditions, enabling digital pets to exist in contexts beyond traditional screens.

Traditional environmental monitoring faces significant challenges: data sparsity, lack of real-time granularity, and verification difficulties. Government sensors provide only generalized data that misses hyperlocal variations in air quality, noise pollution, and other environmental factors that directly impact daily life.

This creates blind spots in urban environments where pollution levels can vary dramatically between neighborhoods or even streets.

The P-mini addresses these gaps by creating a grassroots network of sensors collecting street-level data. What sets OKZOO apart from conventional DePin networks is its innovative approach to user engagement. Rather than relying solely on financial incentives, the P-mini integrates virtual pets that respond to environmental surroundings, transforming data collection into an interactive, emotional experience.

In-House Manufacturing Capabilities

A key competitive advantage for OKZOO lies in its in-house manufacturing capabilities. Unlike many projects that rely on third-party manufacturers, OKZOO controls its hardware production process, ensuring scalability, quality control, and faster iteration based on user feedback. This vertical integration allows for rapid adaptation to market demands and technological advances.

The ecosystem operates on an incentive model that rewards users for running P-mini devices and contributing environmental data. These contributions establish a comprehensive database powering sophisticated AI applications ranging from customized health guidance to urban planning solutions.

As environmental awareness becomes increasingly important, OKZOO positions itself at the intersection of utility and engagement. By making data collection enjoyable through pet companions, the project creates sustainable user participation while addressing real environmental monitoring needs.

For a market seeking practical applications, OKZOO’s unique positioning across AI, environmental monitoring, and hardware manufacturing presents a compelling vision for addressing real-world challenges while creating engaging user experiences.

Website: https://okzoo.app/en
X: https://x.com/okzoo_app

 

Petal Ads Hosts “Think Tank 2025” Seminar in Japan to Empower Japanese Companies’ Global Expansion

TOKYO, April 26, 2025 /PRNewswire/ — Petal Ads, Huawei’s leading global mobile advertising platform, today successfully hosted the “Think Tank 2025” seminar in Japan. The event convened prominent brands and domestic agencies from the travel, beauty, luxury goods and lifestyle services sectors to showcase Huawei’s all-scenario intelligent advertising solutions built on the HarmonyOS ecosystem, offering Japanese enterprises fresh digital-marketing strategies for entering the Chinese and wider global markets.

As a technology company deeply rooted in Japan for nearly two decades, Huawei leverages its global ecosystem and the innovation of HarmonyOS to continuously empower partners’ digital transformation. “Through in-depth local insights, we have built an intelligent advertising platform that connects global users,” said Zhou Rong, Director of Asia-Pacific Ecosystem Development and Operations at Huawei Consumer Business Group. “Petal Ads’ unique all-scenario solutions not only precisely reach segmented audiences but also help Japanese brands unlock commercial value in cross-cultural communication.”

At the seminar, Yang Yang, Global Marketing Director of Huawei Ads, presented an integrated marketing strategy within the HarmonyOS ecosystem. Syaliza Abd Aziz, Japan representative of the Malaysia Tourism Promotion Board, discussed her organization’s strategic partnership with Petal Ads on Visit Malaysia 2026. Colin Duan, Chief Product Officer of third-party data firm QuestMobile, used detailed analytics to decode Chinese internet users’ consumption patterns in travel, beauty and other industries, providing decision-making insights for Japanese companies’ local-market campaigns. Fukuzumi Ryo, co-founder of leading Japanese ad agency Unbot, shared multiple success stories on site, demonstrating Petal Ads’ technical strengths in precise customer acquisition and performance conversion in Japan.

The upgraded “Think Tank 2025” marks a significant milestone in Petal Ads’ globalization strategy. With three core advantages—intelligent ad technology, a premium global user base and customizable all-scenario solutions—the platform now delivers monetization services to 53,000 apps across more than 200 industries worldwide. Looking ahead, Petal Ads will deepen strategic collaborations with its Japanese partners and continue to foster more high-quality brands’ international growth through an innovative digital-marketing ecosystem.

For more information, please visit: https://ads.huawei.com/

About Petal Ads

Petal Ads is Huawei Terminal Cloud Services’ global commercial-service platform, dedicated to providing advertisers and developers with intelligent marketing and traffic-monetization solutions. As of March 2023, the platform spans over 200 industry verticals and operates in more than 170 countries and regions, continually empowering partners’ commercial growth and brand enhancement via HarmonyOS’s all-scenario intelligent distribution capabilities.

Spiking and Searce Join Forces to Launch Cutting-Edge SaaS Solution on Google Cloud Marketplace


Singapore, Singapore – Newsfile Corp. – April 25, 2025 – Spiking, a leading fintech innovator, has partnered with Searce to launch a cutting-edge software as a service (SaaS) solution on the Google Cloud Marketplace.

This collaboration combines Spiking’s financial analytics and Searce’s technical consulting expertise. The result is TradeGPT, an advanced AI solution with Retrieval-Augmented Generation (RAG) capabilities, being made available on the Google Cloud Marketplace.

Dr. Clemen Chiang, CEO of Aly Pte. Ltd. (Spiking), said: “By developing TradeGPT and enhancing it with RAG capabilities, we’re delivering unparalleled value to our users-combining real-time data insights with Google Cloud’s open, secure-by-design, and planet-scale infrastructure. Our collaboration with Searce exemplifies our mission to empower wealth creation through innovation.”

“We are thrilled to partner with Spiking to bring this visionary project to life. Our team’s expertise in cloud architecture and machine learning, paired with Google Cloud’s workload-optimized infrastructure, has enabled us to fast-track the deployment of a world-class SaaS solution. This collaboration showcases Searce’s commitment toward co-innovating with our clients to ‘Futurify’ their businesses, driving real business outcomes,” said Yash Thakker, Director of Solutions Consulting, Searce.

Driving fintech innovation

Searce is providing services and expertise primarily in software engineering and machine learning. Implementing RAG on an Elasticsearch database hosted on Google Cloud enables TradeGPT to deliver real-time, contextually-rich financial insights. The solution was developed within eight weeks under the AI Cloud Take-Off (AI CTO) pilot program by Google Cloud and Singapore’s Economic Development Board (EDB).

Spiking’s SaaS solution has since been made available on the Google Cloud Marketplace. Over three weeks, Searce’s cloud architects and engineers have ensured seamless onboarding, API integration, and an optimized customer experience. Supported by EDB, this collaboration cements Spiking’s position as a fintech leader.

Advancing Financial Technology

This collaboration delivers cutting-edge financial tools worldwide. Underpinned by Google Cloud infrastructure and enhanced with RAG, TradeGPT offers advanced market analysis, personalized insights, and real-time notifications-setting a new benchmark for fintech innovation.

For more information about Spiking’s SaaS solution on Google Cloud Marketplace, visit www.spiking.com or contact info@spiking.com.

About Spiking
Spiking, through Aly Pte. Ltd., is a Singapore-based fintech innovator dedicated to revolutionizing wealth creation. With its flagship product, TradeGPT, Spiking empowers users with actionable financial insights powered by advanced technology. Learn more at https://spiking.com.

About Searce
Searce is an AI-powered, engineering-led modern tech consultancy that empowers clients to futurify by delivering real business outcomes. Visit www.searce.com for more details.

Media Contact:
Nic Yee
Email: info@spiking.com
Phone: +1-570-SPIKING

Sherly Nyolanda
Email: sherly.nyolanda@searce.com
Phone: +62 87877837073

The issuer is solely responsible for the content of this announcement.

Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality

SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it has released results from four preclinical studies in poster presentations at the 2025 American Association for Cancer Research Annual Meeting (AACR 2025). These four posters feature Antengene’s four highly differentiated and high-potential programs, including ATG-201 (CD19 x CD3 TCE) and ATG-042 (MTAPnull-selective PRMT5 Inhibitor), which are poised to enter clinical development in the second half of 2025; ATG-110 (LY6G6D x CD3 TCE), which was developed on the AnTenGagerTM TCE 2.0 platform for the treatment of microsatellite stable colorectal cancer; and a companion diagnostic antibody developed to assess CD24 expression and guide clinical studies of CD24-targeted therapies.

Details of the Poster Presentations:
ATG-201 (CD19 x CD3 T cell engager)
Title: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases
Abstract Number: 7326
Session Category: Immunology
Session Title: T Cell Engagers and Novel Antibody-Based Therapies
Date: April 30, 2025
Time: 9:00 AM – 12:00 PM (Central Time)
          10:00 PM, April 30, 2025 – 1:00 AM, May 1, 2025 (Beijing Time)
Location: Poster Section 40
•   Introduction: By depleting autoreactive B cells, CD19-targeted CAR-T have shown early yet promising efficacy in treating patients with B cell-driven autoimmune diseases. However, the clinical application of TCE continues to be greatly hindered by the unfavorable pharmacokinetics and toxicity associated with cytokine release syndrome. To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in vitro studies for binding affinity, T cell dependent cytotoxicity (TDCC) cytokine release, and drug developability. The in vivo anti-lymphoma efficacy and pharmacodynamic effect were evaluated in Raji xenograft model. The tissue resident B cell depletion was assessed in CD34+ hematopoietic stem cells humanized mice. Pharmacokinetic parameters of ATG-201 were evaluated in normal Balb/c mice.
•   Results: ATG-201 demonstrated high affinity binding to CD19, limited T cell binding before CD19 crosslinking, highly potent CD19-dependent T cell cytotoxicity against CD19+ B cells, as well as enhanced naïve B cell depletion with reduced cytokine release compared to clinical benchmarks. In lymphoma models, the study observed potent in vivo efficacy with reduced cytokine release. In CD34+ hematopoietic stem cells humanized mice, ATG-201 was able to induce complete B cell depletion with reduced cytokine release. ATG-201 has a mAb-like pharmacokinetic profile in wild type mice and good drug developability. Moreover, surrogate CD19 x CD3 AnTenGager TCE displayed potent efficacy in MRL/lpr spontaneous systemic lupus erythematosus (SLE) mouse models and MOG-Induced EAE models.
•   Conclusions: ATG-201 demonstrated CD19-dependent CD3 binding and activation, inducing effective B cell depletion in vitro and in vivo with low cytokine release, which provides potential for the treatment of B cell malignancies and B cell related autoimmune diseases. ATG-201 is poised to enter clinical development in the second half of 2025.

ATG-042 (MTAPnull-selective PRMT5 Inhibitor)
Title: Preclinical characterization of ATG-042, a novel MTAPnull-selective PRMT5 inhibitor
Abstract Number: 4230
Session Category: Experimental and Molecular Therapeutics
Session Title: HDAC and Methyltransferase Inhibitors
Date: April 29, 2025
Time: 9:00 AM – 12:00 PM (Central Time)
          10:00 PM, April 29, 2025 – 1:00 AM, April 30, 2025 (Beijing Time)
Location: Poster Section 16
•   Introduction: Targeting the PRMT5-MTA complex has become a promising strategy for treating MTAPnull cancer in a synthetically lethal manner, avoiding on-target-off-tumor hematological toxicity when using first-generation, non-selective PRMT5 inhibitors. Herein, Antengene developed ATG-042, a novel MTAPnull-selective PRMT5 small molecule inhibitor with good brain penetration. In this study, the in vitro activity and MTAP selectivity of ATG-042 were profiled using HCT116 MTAP wild type (wt) cells, HCT116 MTAP knock out (ko) cells and multiple endogenous MTAPnull cell lines. The in vivo efficacy was tested in cell derived xenograft (CDX) mouse models with HCT116 MTAP wt cells, HCT116 MTAP ko cells, LU99 cells (MTAPnull) and U87MG-luc (MTAPnull). The pharmacokinetic and toxicological properties were assessed with corresponding assay methods.
•   Results: ATG-042 showed excellent anti-proliferative activities on multiple endogenous MTAPnull cell lines with IC50 values between 10nM and 100nM. ATG-042 demonstrated high permeability, good metabolic stability, and low risk of drug-drug interaction. In vivo PK study shows that ATG-042 is well absorbed, with a dose-dependent increase in plasma distribution and high oral bioavailability in mice, SD rats and beagle dogs. Furthermore, ATG-042 is brain-penetrable (B/P ratio=51% in mice; KPuubrain=0.73 in rats). ATG-042 showed robust in vivo efficacy in both subcutaneous CDX models (HCT116 -MTAP ko, LU99) and orthotopic CDX model (U87MG-luc) as a single agent. In addition, ATG-042 also exhibited potential synergy in combination with other drugs for antitumor therapy.
•   Conclusions: ATG-042 is an oral MTAPnull-selective PRMT5 inhibitor with potent efficacy against MTAPnull tumor. It also demonstrated good tolerability and brain penetrability. ATG-042 is poised to enter clinical development in the second half of 2025.

ATG-110 (LY6G6D x CD3 T cell engager)
Title: ATG-110, a novel “2+1” LY6G6D-targeted T-cell Engager (TCE) with high potency for the treatment of MSS colorectal cancer
Abstract Number: 3509
Session Category: Immunology
Session Title: T Cell Engagers
Date: April 28, 2025
Time: 2:00 PM – 5:00 PM (Central Time)
          3:00 AM – 6:00 AM, April 29, 2025 (Beijing Time)
Location: Poster Section 38
•   Introduction: Colorectal cancer (CRC) is one of the most common cancers worldwide and requires more effective and safer therapies to improve the poor survival outcome, particularly in patients with microsatellite stable (MSS) colorectal cancer, who exhibit primary resistance to immune checkpoint inhibitors and lack effective treatment options. T cell engagers have shown encouraging efficacy in treating hematological malignancies, while exhibiting suboptimal clinical efficacies in solid tumors. The risk of cytokine release syndrome (CRS) remains as a significant challenge clinically. ATG-110 is a novel “2+1” LY6G6D x CD3 TCE developed by Antengene. In this study, ATG-110 was evaluated in a series of preclinical in vitro studies for binding affinity, T cell activation and cytokine release, T cell dependent cytotoxicity (TDCC), and drug developability. The in vivo anti-tumor efficacy was evaluated in PBMC-humanized immunodeficient NDG mice engrafted with LY6G6Dmedium-expression HT55 or LY6G6Dvery low-expression SW480 MSS CRC cells.
•   Results: ATG-110 binds to LY6G6D-positive cell lines, including LY6G6D-overexpression 293T and HT55 with the nanomolar grade EC50. The CD3 binding site of ATG-110 is concealed by the LY6G6D Fab arm before binding to LY6G6D, due to the steric hindrance. Therefore, ATG-110 demonstrated limited binding capability to CD3+ cells before LY6G6D crosslinking. It activates T cells and induces cytokine release only in the presence of LY6G6D+ cells. In vitro, ATG-110 resulted in potent T cell dependent cytotoxicity with single-digit pM IC50 values on HT55 cells. ATG-110 also showed highly potent in vitro efficacy against LY6G6Dlow-expression cells. ATG-110 exhibited a low risk of inducing cytokine release syndrome. ATG-110 demonstrated potent anti-tumor activity in PBMC-humanized HT55 xenograft model. Furthermore, ATG-110 also demonstrated good drug developability.
•   Conclusions: ATG-110 demonstrated LY6G6D-dependent CD3 binding and activation with low risk of CRS. It showed powerful in vitro and in vivo anti-tumor efficacy against colorectal cancer, which warrants further clinical evaluation.

ATG-1144 (CD24 CDx Antibody)
Title: Development of a diagnostic antibody for CD24 targeted therapy
Abstract Number: 671
Session Category: Clinical Research
Session Title: Diagnostic Biomarkers 2
Date: April 27, 2025
Time: 2:00 PM – 5:00 PM (Central Time)
          3:00 AM – 6:00 AM, April 28, 2025 (Beijing Time)
Location: Poster Section 29
•   Introduction: CD24 has emerged as a promising therapeutic target for anti-cancer treatment. Several clinical trials are being conducted to evaluate the safety and efficacy of CD24-targeted therapies. Here, Antengene developed and characterized an anti-CD24 diagnostic antibody to enhance the screening and selection of patients based on CD24 expression. In this study, the authors described the discovery of the diagnostic antibody, and the evaluation of accuracy, sensitivity (selectivity), specificity, and assay precision of the antibody.
•   Results: Monoclonal antibody clone ATG-1144 binds to the hCD24 core peptide in ELISA with an EC50 of 0.06 nM. Distinct membrane staining on human normal esophageal tissue FFPE specimens can also be observed with IHC staining using ATG-1144. For accuracy assessment, six CDX and twenty human specimens, comprising both positive and negative specimens (including solid tumors and B-cell non-Hodgkin lymphomas), were validated. Samples exhibiting high, medium, and low CD24 expression levels were evaluated for sensitivity and specificity, and the interpreted results aligned with the reference outcomes. FFPE tissues from three distinct patients were evaluated for assay precision assessment. The TMA IHC staining result revealed that 50-80% of patients with lung, breast, bladder, ovarian, or liver cancer have CD24 expression on tumor cell surface with low expression in the para-cancerous normal tissue.
•   Conclusions: ATG-1144 specifically binds to human CD24 with high sensitivity as demonstrated by IHC staining. The development and validation of the method have been finalized using Leica Bond III platforms. These data suggest a potential diagnostic use of ATG-1144 for identifying CD24+ patients.

About Antengene
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.
Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com 
Mobile: +86 13062747000

51Talk Online Education Group Files Annual Report on Form 20-F for Fiscal Year of 2024

SINGAPORE, April 26, 2025 /PRNewswire/ — 51Talk Online Education Group (“51Talk” or the “Company”) (NYSE American: COE), a global online education platform with core expertise in English education, announced  that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (“SEC”) on April 25, 2025.

The annual report can be accessed on the Company’s investor relations website at http://ir.51talk.com/ as well as the SEC’s website at http://www.sec.gov. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements for the fiscal year ended December 31, 2024, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company’s IR Department at ir@51talk.com.

About 51Talk Online Education Group 

51Talk Online Education Group (NYSE American: COE) is a global online education platform with core expertise in English education. The Company’s mission is to make quality education accessible and affordable. The Company’s online and mobile education platforms enable students to take live interactive English lessons, on demand. The Company connects its students with a large pool of highly qualified teachers that it assembled using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students. 

For more information, please visit http://ir.51talk.com.

Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU,China, April 26, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for limertinib as the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations. Innovent and ASK Pharm entered into a commercial collaboration agreement for limertinib in Mainland China in 2024.

The approval of this new indication is supported by positive results from a randomized, double-blind, positive-controlled Phase 3 clinical trial. A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib. The primary endpoint was progression-free survival (PFS), as assed by an independent review committee (IRC).

The data showed that limertinib significantly prolonged median PFS compared to gefitinib (20.7 months vs. 9.7 months), representing a 56% risk reduction in disease progression or death (hazard ratio [HR] 0.44; 95% CI: 0.34–0.58; p < 0.0001). In patients with central nervous system (CNS) lesions at baseline, median CNS PFS was also significantly longer with limertinib (20.7 months vs. 7.1 months), corresponding to a 72% risk reduction for CNS progression or death (HR 0.28; 95% CI: 0.10–0.82; p = 0.0136), underscoring its robust intracranial activity and clinical utility in such population with high-unmet-needs.

The safety profile of limertinib was consistent with that of known EGFR-targeted therapies. Adverse events were predominantly mild to moderate and well-tolerated, with no new safety signals identified during the clinical trial. Full data and analysis from this pivotal Phase 3 study will be published in academic journals.

“Limertinib has demonstrated exceptional efficacy and safety as first-line therapy in patients with EGFR-muted locally advanced or metastatic NSCLC, including notable efficacy in those with brain metastases. The approval of this first-line indication introduces a new treatment option for Chinese patients, addressing a critical clinical need in this population.” said Professor Shi Yuankai, MD, Department of Medical Oncology at Chinese Academy of Medical Sciences and Principal Investigator of the Phase 3 Clinical Study.

Dr. Hui Zhou, Senior Vice President of Innovent, stated:”We are delighted that both the first-line and second-line indications for limertinib have been successively approved. As a next-generation EGFR TKI, limertinib is poised to significantly improve survival outcomes for mutation-positive patients. Innovent has built a rich portfolio of precision therapies for lung cancer—including limertinib, Retsevmo®(selpercatinib), Dupert®(fulzerasib) and DOVBLERON® (taletrectinib)—with ongoing efforts to enhance their synergistic value. We will continue to work closely with Ask Pharm to ensure that limertinib brings a new hope to the broad population of patients with EGFR-mutated NSCLC.”

Mr. Jingfei Ma, CEO of ASK Pharm, stated: “Within a few months, limertinib has obtained approvals for both second-line and first-line indications. The approval of the first-line indication further expands its clinical applicability. Meanwhile, ASK Pharm is advancing a clinical trial of limertinib in combination with the cMET inhibitor ASKC202 for patients with NSCLC resistant to third-generation EGFR-TKIs. We look forward to working with our partner Innovent to accelerate the accessibility of limertinib for more patients in need.”

About EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Lung cancer remains one of the deadliest and most common cancers globally[1], with NSCLC accounting for approximately 85% of cases. Around 70% of NSCLC patients are diagnosed at locally advanced or metastatic stages that are not amenable to surgical resection. EGFR mutations are particularly prevalent among Asian NSCLC patients, affecting 30% to 50% of cases. EGFR-TKIs are the recommended standard of care in the first-line setting, with third-generation EGFR-TKIs offering the broadest treatment applicability.

About Limertinib

Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights. It has been approved by the China’s NMPA for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), who have previously experienced disease progression during or after treatment with EGFR TKI; and 2) the first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations.

In October 2024, Innovent and ASK Pharm entered into a strategic collaboration and license agreement for limertinib in Mainland China.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1 Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2 Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

About Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)

Founded in January 2003, Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with manufacture, marketing promotion and sales of proprietary pharmaceuticals, fine chemicals and health-care products. ASK Pharm specializes in digestive disease, multidrug resistant infection, oncology and chronic disease areas.

ASK Pharm focuses on the R&D of small-molecule targeted innovative drugs and immuno-oncology biologic drugs. Currently, there are 48 major research projects, including 11 disclosed key projects focused on innovative chemical and biologic drugs. Among these, ASKC109 (maltol iron capsules) and ASKB589 (Claudin18.2 monoclonal antibody) are in Phase III clinical trials. ASK Pharm has Ranked among the top 20 best industrial enterprises in China’s pharmaceutical R&D pipeline for 14 consecutive years and it has also received numerous honors such as “Top Ten National R&D Innovators”, “Best National Enterprise for Investment”, and “National Torch Program High-Tech Enterprises”.

For more information, visit www.ask-pharm.com.

Innovent’s Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Reference

[1] Bray F, et al. Global cancer statistics 2022. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.